Trial · NCT00254423
Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
NCT00254423, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2026-01-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia. Trials, record NCT00254423. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00254423
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
- NCT number
- NCT00254423
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 150 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
- Interventions
- Dasatinib
- First posted
- 2005-11-16
- Last updated
- 2026-01-15
- Results first posted
- 2026-01-15
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With a Major Molecular Response at 12 Months | 12 months | Major Molecular Response (MMR) is BCR-ABL/ABL ratio \</= 0.05 |
| Secondary | Overall Survival | Up to 19 years, 4 months and 6 days | Time from date of treatment start until date of death due to any cause or last Follow-up. |
| Secondary | Participants With Complete Cytogenic Response (CCR) | Up to 19 years, 4 months and 6 days | Complete Cytogenic Response (CCR) is Ph positive 0% |
| Secondary | Participants Who Developed the ABL Mutations | Up to 19 years, 4 months and 6 days | ABL mutations will be assesses during treatment through Quanitiative PCR (qPCR) (RT-qPCR) or ABM mutational analysis using Sanger Sequencing or next-Generation Sequencing (NGS). |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With a Major Molecular Response at 12 Months | 12 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Overall Survival | Up to 19 years, 4 months and 6 days | Months | MEDIAN | |
| SECONDARY | Participants With Complete Cytogenic Response (CCR) | Up to 19 years, 4 months and 6 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Participants Who Developed the ABL Mutations | Up to 19 years, 4 months and 6 days | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With a Major Molecular Response at 12 Months | Dasatinib | 103 | Participants | ||
| Overall Survival | Dasatinib | NA | Full Range 0.3 to 232 | Months | |
| Participants With Complete Cytogenic Response (CCR) | Dasatinib | 140 | Participants | ||
| Participants Who Developed the ABL Mutations | Dasatinib | 7 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dasatinib | 150 | |
| Overall Study | COMPLETED | Dasatinib | 150 | |
| Overall Study | NOT COMPLETED | Dasatinib | 0 |
Source ClinicalTrials.gov
Adverse events136
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ACNE | Skin and subcutaneous tissue disorders | Dasatinib | 16 | 150 | 20 |
| other | ALKALINE PHOSPHATASE | Metabolism and nutrition disorders | Dasatinib | 8 | 150 | 9 |
| other | ALLERGIC RHINITIS | Respiratory, thoracic and mediastinal disorders | Dasatinib | 8 | 150 | 12 |
| other | ALLERGY/IMMUNOLOGY (OTHER) | Immune system disorders | Dasatinib | 8 | 150 | 10 |
| other | ALOPECIA | Skin and subcutaneous tissue disorders | Dasatinib | 15 | 150 | 16 |
| other | ALT SGPT | Investigations | Dasatinib | 15 | 150 | 30 |
| other | ANEMIA | Blood and lymphatic system disorders | Dasatinib | 27 | 150 | 33 |
| other | ANOREXIA | Metabolism and nutrition disorders | Dasatinib | 7 | 150 | 7 |
| other | ARTHRITIS | Musculoskeletal and connective tissue disorders | Dasatinib | 8 | 150 | 13 |
| other | AST SGOT | Investigations | Dasatinib | 25 | 150 | 32 |
1 to 10 of 136Source ClinicalTrials.gov
See all 136 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dasatinib | 4 | 150 |
| Total, other adverse events | Dasatinib | 144 | 150 |
| Total, serious adverse events | Dasatinib | 34 | 150 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA016672 | The University of Texas MD Anderson Cancer Center Support Grant (CCSG) | KOONG, ALBERT | UNIVERSITY OF TX MD ANDERSON CAN CTR | NATIONAL CANCER INSTITUTE | 1985 to 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00254423
GET https://conductscience.org/api/trials/v1/NCT00254423/events?page=2